Drug updated on 9/4/2024
Dosage Form | Injection (intravenous; 420 mg/14 mL) |
Drug Class | HER2/neu receptor antagonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
- Indicated for use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
- Indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.
Latest News
Summary
- Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also used in combination with trastuzumab and chemotherapy as neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. Additionally, it is indicated in combination with trastuzumab and chemotherapy as adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence.
- This summary is based on the review of 27 systematic review(s)/meta-analysis(es). [1-27]
- Progression-Free Survival (PFS) and Overall Survival (OS): Dual HER2-targeted therapy, especially the combination of trastuzumab and pertuzumab, demonstrated significant improvements in PFS and OS across various studies (e.g., HR = 1.40 for OS, HR = 1.36 for PFS), with dual therapy often outperforming single-targeted therapies in HER2-positive breast cancer.
- Pathologic Complete Response (pCR): The addition of pertuzumab to treatment regimens increased pCR rates significantly (e.g., OR = 2.10). Dual HER2-targeted therapies consistently led to higher pCR rates compared to monotherapies in HER2-positive breast cancer, particularly when combined with taxane-based chemotherapy.
- Overall Survival (OS): Treatment with trastuzumab-deruxtecan was associated with prolonged OS compared to other HER2-targeted therapies, including trastuzumab-emtansine, in HER2-positive breast cancer.
- Combination Therapy: Chemotherapy combined with dual HER2-targeted agents, particularly trastuzumab and pertuzumab, was found to provide the best outcomes in terms of efficacy, particularly in HER2+ metastatic breast cancer, although these regimens carried an increased risk of certain adverse events.
- The most common adverse reactions in the dual-targeted therapy group were infections, nervous system disorders, gastrointestinal disorders, respiratory disorders, skin disorders, and general disorders. Incidences of blood system disorders and liver dysfunction were lower compared to the single-targeted therapy group.
- Higher incidence of grade ≥3 adverse events such as diarrhea, anemia, and rash was observed in the experimental group receiving pertuzumab.
- Dual-targeted therapy with trastuzumab and pertuzumab was associated with the highest risk of inducing cardiac events.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Perjeta (pertuzumab) Prescribing Information. | 2021 | Genentech Inc., South San Francisco, CA |